JP2016169229A5 - - Google Patents

Download PDF

Info

Publication number
JP2016169229A5
JP2016169229A5 JP2016120503A JP2016120503A JP2016169229A5 JP 2016169229 A5 JP2016169229 A5 JP 2016169229A5 JP 2016120503 A JP2016120503 A JP 2016120503A JP 2016120503 A JP2016120503 A JP 2016120503A JP 2016169229 A5 JP2016169229 A5 JP 2016169229A5
Authority
JP
Japan
Prior art keywords
pik3ca
subject
mutation
neratinib
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016120503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016169229A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016169229A publication Critical patent/JP2016169229A/ja
Publication of JP2016169229A5 publication Critical patent/JP2016169229A5/ja
Withdrawn legal-status Critical Current

Links

JP2016120503A 2009-12-11 2016-06-17 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー Withdrawn JP2016169229A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28582109P 2009-12-11 2009-12-11
US61/285,821 2009-12-11
US28787209P 2009-12-18 2009-12-18
US61/287,872 2009-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015051863A Division JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017038956A Division JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Publications (2)

Publication Number Publication Date
JP2016169229A JP2016169229A (ja) 2016-09-23
JP2016169229A5 true JP2016169229A5 (enExample) 2017-04-06

Family

ID=43628745

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2010273484A Withdrawn JP2011121944A (ja) 2009-12-11 2010-12-08 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2015051863A Pending JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2016120503A Withdrawn JP2016169229A (ja) 2009-12-11 2016-06-17 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2017038956A Withdrawn JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2018246698A Withdrawn JP2019052187A (ja) 2009-12-11 2018-12-28 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2020119091A Withdrawn JP2020169212A (ja) 2009-12-11 2020-07-10 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2021192872A Pending JP2022022296A (ja) 2009-12-11 2021-11-29 ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010273484A Withdrawn JP2011121944A (ja) 2009-12-11 2010-12-08 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2015051863A Pending JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017038956A Withdrawn JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2018246698A Withdrawn JP2019052187A (ja) 2009-12-11 2018-12-28 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2020119091A Withdrawn JP2020169212A (ja) 2009-12-11 2020-07-10 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2021192872A Pending JP2022022296A (ja) 2009-12-11 2021-11-29 ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー

Country Status (5)

Country Link
US (4) US20130189274A1 (enExample)
EP (2) EP2510121A1 (enExample)
JP (7) JP2011121944A (enExample)
CA (1) CA2783743C (enExample)
WO (1) WO2011070499A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN102724962B (zh) 2009-11-09 2017-05-17 惠氏有限责任公司 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途
JP2014529298A (ja) * 2011-07-28 2014-11-06 ジェネンテック， インコーポレイテッド Ｐｉｋ３ｃａｈ１０４７ｒノックイン非ヒト動物乳癌モデル
WO2013083810A1 (en) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
KR101915942B1 (ko) * 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CN105274188A (zh) * 2014-05-29 2016-01-27 北京雅康博生物科技有限公司 Pik3ca基因突变检测试剂盒
EP3294314A4 (en) * 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
KR20190054826A (ko) * 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
IT201800010730A1 (it) * 2018-11-30 2020-05-30 Univ Degli Studi Milano Metodo per classificare pazienti affetti da tumore alla mammella idonei per immunoterapia
EP3920911A4 (en) 2019-02-06 2023-03-08 Venthera, Inc. Topical phosphoinositide 3-kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
US8105768B2 (en) * 2005-03-09 2012-01-31 Abbott Laboratories Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
WO2006122053A2 (en) * 2005-05-09 2006-11-16 Ariad Gene Therapeutics, Inc. Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
EP2851091B1 (en) * 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Similar Documents

Publication Publication Date Title
JP2016169229A5 (enExample)
Sexton et al. Gastric cancer: a comprehensive review of current and future treatment strategies
Molinari et al. Heterogeneity in colorectal cancer: a challenge for personalized medicine?
Sukawa et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer
Duan et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine
Ting et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma
Nomura et al. Distinct molecular profile of diffuse cerebellar gliomas
EP2944961A1 (en) Markers for cancer prognosis and therapy and methods of use
Sung et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy
Li et al. Current status of ctDNA in precision oncology for hepatocellular carcinoma
CA2948351A1 (en) Biomarkers for response to pi3k inhibitors
CN105705658A (zh) 随时间检测疾病中的突变
Fisher et al. Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?
Kim et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
Hufnagl et al. A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients
US12325880B2 (en) Identification of PDE3 modulator responsive cancers
JP2014503180A5 (enExample)
CN110452986A (zh) 一种检测结直肠癌相关基因变异的引物及其应用
Stewart et al. New therapies for clear cell ovarian carcinoma
CA2819080A1 (en) Agtr1 as a marker for bevacizumab combination therapies
Yao et al. Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Zavarykina et al. Circulating tumor DNA is a variant of liquid biopsy with predictive and prognostic clinical value in breast cancer patients
Agirre-Lizaso et al. Targeting the heterogeneous tumour-associated macrophages in hepatocellular carcinoma
WO2017197351A1 (en) Methods for identifying clonal mutations and treating cancer
Zhuo et al. LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer